170 related articles for article (PubMed ID: 9373241)
41. Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism.
Pepper C; Thomas A; Fegan C; Hoy T; Bentley P
Leuk Lymphoma; 2003 Feb; 44(2):337-42. PubMed ID: 12688354
[TBL] [Abstract][Full Text] [Related]
42. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
[TBL] [Abstract][Full Text] [Related]
43. Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis.
Jorda EG; Verdaguer E; Canudas AM; Jiménez A; Bruna A; Caelles C; Bravo R; Escubedo E; Pubill D; Camarasa J; Pallàs M; Camins A
Neuropharmacology; 2003 Oct; 45(5):672-83. PubMed ID: 12941380
[TBL] [Abstract][Full Text] [Related]
44. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
Liu X; Shi S; Lam F; Pepper C; Fischer PM; Wang S
Int J Cancer; 2012 Mar; 130(5):1216-26. PubMed ID: 21484792
[TBL] [Abstract][Full Text] [Related]
45. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
[TBL] [Abstract][Full Text] [Related]
46. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.
Bible KC; Kaufmann SH
Cancer Res; 1996 Nov; 56(21):4856-61. PubMed ID: 8895733
[TBL] [Abstract][Full Text] [Related]
47. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase.
Kaiser A; Nishi K; Gorin FA; Walsh DA; Bradbury EM; Schnier JB
Arch Biochem Biophys; 2001 Feb; 386(2):179-87. PubMed ID: 11368340
[TBL] [Abstract][Full Text] [Related]
48. Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells.
Takada Y; Sethi G; Sung B; Aggarwal BB
Mol Pharmacol; 2008 May; 73(5):1549-57. PubMed ID: 18287248
[TBL] [Abstract][Full Text] [Related]
49. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction.
Litz J; Carlson P; Warshamana-Greene GS; Grant S; Krystal GW
Clin Cancer Res; 2003 Oct; 9(12):4586-94. PubMed ID: 14555534
[TBL] [Abstract][Full Text] [Related]
50. Mechanisms of action of flavopiridol.
Sedlacek HH
Crit Rev Oncol Hematol; 2001 May; 38(2):139-70. PubMed ID: 11311660
[TBL] [Abstract][Full Text] [Related]
51. Flavones and polyphenols inhibit the NO pathway during apoptosis of leukemia B-cells.
Quiney C; Dauzonne D; Kern C; Fourneron JD; Izard JC; Mohammad RM; Kolb JP; Billard C
Leuk Res; 2004 Aug; 28(8):851-61. PubMed ID: 15203283
[TBL] [Abstract][Full Text] [Related]
52. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
Pepper C; Thomas A; Hoy T; Fegan C; Bentley P
Br J Haematol; 2001 Jul; 114(1):70-7. PubMed ID: 11472347
[TBL] [Abstract][Full Text] [Related]
53. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI
Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540
[TBL] [Abstract][Full Text] [Related]
54. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
[TBL] [Abstract][Full Text] [Related]
55. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
56. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Senderowicz AM
Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375
[TBL] [Abstract][Full Text] [Related]
57. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
[TBL] [Abstract][Full Text] [Related]
58. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
Mahoney E; Lucas DM; Gupta SV; Wagner AJ; Herman SE; Smith LL; Yeh YY; Andritsos L; Jones JA; Flynn JM; Blum KA; Zhang X; Lehman A; Kong H; Gurcan M; Grever MR; Johnson AJ; Byrd JC
Blood; 2012 Aug; 120(6):1262-73. PubMed ID: 22740450
[TBL] [Abstract][Full Text] [Related]
59. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.
Arguello F; Alexander M; Sterry JA; Tudor G; Smith EM; Kalavar NT; Greene JF; Koss W; Morgan CD; Stinson SF; Siford TJ; Alvord WG; Klabansky RL; Sausville EA
Blood; 1998 Apr; 91(7):2482-90. PubMed ID: 9516149
[TBL] [Abstract][Full Text] [Related]
60. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed.
Hara T; Omura-Minamisawa M; Kang Y; Cheng C; Inoue T
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1485-95. PubMed ID: 18640498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
